MedTrace Logo

Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China

NCT04421495 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 608

Last updated 2022-07-07

No results posted yet for this study

Summary

The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.

Conditions

  • Multidrug Resistant Tuberculosis

Interventions

DRUG

Delamanid

the eligible patients will be give damanid-containing regimen

Sponsors & Collaborators

  • Beijing Chest Hospital

    lead OTHER

Principal Investigators

  • Liang Li · Beijing Chest Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-16
Primary Completion
2022-06-16
Completion
2024-07-16

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421495 on ClinicalTrials.gov